Dr. Bruce Chabner serves as Allen Distinguished Investigator, Clinical Director Emeritus for the Massachusetts General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School.

His main fields of research focus on the biochemistry and pharmacology of folate antagonists, experimental therapeutics, and clinical trial design.

He has served as the Associate Director of Clinical Science at Dana Farber/Harvard Cancer Center (2000-2010) and has held additional academic appointments, including the position of Director of the Division of Cancer Treatment of the National Cancer Institute from 1982 to 1995.

Dr. Chabner received his B.A., summa cum laude, from Yale College (1961) and an MD, cum laude, from Harvard Medical School (1965).

He has authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers, now in its fourth edition. Dr. Chabner has contributed to the Goodman and Gilman textbook of Pharmacology and has authored chapters for numerous other textbooks of internal medicine, hematology, oncology and pharmacology.

Over the years, Dr. Chabner has received awards including Phi Beta Kappa, Alpha Omega, Alpha, the Public Health Service's Distinguished Service Medal, the Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research. In 2006, he was the first recipient of the Bob Pinedo Award for Contributions to Improvement in the Care of Cancer Patients.

Dr. Chabner is a senior editor for The Oncologist and serves on the executive advisory boards for some of the industry’s leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the National Cancer Institute, and chaired the NCAB from (2010-2012).